MedCAC Review Of ESAs In Renal Disease To Help Determine Whether NCD Is Needed, CMS Official Says

The Medicare Evidence Development and Coverage Advisory Committee reviewed the safety of erythropoiesis stimulating agents in chronic kidney disease at a March 24 meeting.